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Background: Type 2 diabetes mellitus (DM) patients have variable response profiles to antiplatelet therapy. The effects of pharmacogenetic 
determinants on platelet function profiles and cardiovascular outcomes in type 2 DM patients are unknown. The aims of this study were to assess 
the association between genetic variants in the insulin receptor substrate-1 (IRS-1) gene, platelet function profiles, and long-term clinical outcomes 
in type 2 DM patients with stable coronary artery disease while on aspirin and clopidogrel therapy.
Methods: This is a prospective observational study using longitudinal data including 187 type 2 DM patients with stable coronary artery disease on 
aspirin and clopidogrel therapy. The association between genetic variants in the IRS-1 gene and platelet function profiles and the relation of platelet 
function and IRS-1 genetic variants to the risk of major adverse cardiac events (MACE) during 2 year follow-up were determined.
Results: Seven tagSNPs (rs11683087, rs2251692, rs1801278, rs1801123, rs6725330, rs1896832, rs956115) with an estimated prediction 
value of 97.56% were identified. Carriers of the C allele of the rs956115 marker (GC and CC genotypes; approximately 20% of the study population) 
were more frequent in patients with high posttreatment platelet reactivity HPPR defined by adenosine diphosphate (ADP) stimuli [44.4% vs 20.5%; 
odds ratio (OR) 3.1, 95% confidence intervals (CI) 1.44-6.67; p=0.006]. HPPR patients were at higher risk of MACE [28.0% vs 10.9%; hazard ratio 
(HR), 2.90; 95% CI, 1.38-6.11; p=0.005]. C allele carriers of the rs956115 marker were more commonly associated with a hyperreactive platelet 
phenotype defined by ADP as well as collagen stimuli. Carriers of the C allele of the rs956115 marker also had a significantly higher risk of MACE 
compared to non-carriers (30.6% vs 11.4%; HR, 2.88; 95% CI, 1.35-6.14; p=0.006).
Conclusions: Among type 2 DM patients, carriers of the C allele of the rs956115 marker of the IRS-1 gene had a hyperreactive platelet phenotype 
and a higher rate of MACE than did noncarriers.
